Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
Mol Pharm. 2021 Feb 1;18(2):539-549. doi: 10.1021/acs.molpharmaceut.0c00295. Epub 2020 Jun 19.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that results in severe inflammatory microenvironments in the joint tissues. In clinics, disease-modifying antirheumatic drugs (DMARDs) are generally prescribed to patients with RA, but their long-term use often shows toxicity in some organs such as the gastrointestinal system, skin, and kidneys and immunosuppression-mediated infection. Nanomedicine has emerged as a new therapeutic strategy to efficiently localize the drugs in inflamed joints for the treatment of RA. In this Review, we introduce recent research in the area of nanomedicine for the treatment of RA and discuss how the nanomedicine can be used to deliver therapeutic agents to the inflamed joints and manage the progression of RA, particularly focusing on targeted delivery, controlled drug release, and immune modulation.
类风湿性关节炎（RA）是一种慢性自身免疫性疾病，会导致关节组织中出现严重的炎症微环境。在临床上，通常会给 RA 患者开具疾病修饰抗风湿药物（DMARDs），但这些药物的长期使用往往会导致胃肠道、皮肤和肾脏等器官的毒性以及免疫抑制介导的感染。纳米医学作为一种新的治疗策略，已经出现，它可以有效地将药物靶向递送到炎症关节，从而治疗 RA。在这篇综述中，我们介绍了纳米医学治疗 RA 的最新研究，并讨论了纳米医学如何用于将治疗剂递送到炎症关节以及控制 RA 的进展，特别是侧重于靶向递药、药物控制释放和免疫调节。
